ULBI

Ultralife is a diversified power-and-communications supplier serving government, defense and commercial end markets across two segments (Battery & Energy Products, Communications Systems), grown partly through bolt-on acquisitions (Accutronics, SWE, Excell). The top line is doing its job: FY2025 revenue hit $191M, up 16.2% YoY and nearly double FY2021's $98.3M, and the balance sheet is sound — stockholders' equity of $130M against $86.8M of liabilities (0.67x), current assets of $106M versus $37.3M current liabilities (≈2.8x), and FY2025 operating cash flow still positive at $11.0M. At a $100M market cap the stock trades at 0.5x sales and roughly 0.77x book ($130M equity / 16.7M shares ≈ $7.78 book), so the price already discounts a lot of bad news.

The problem is that the news got bad on the line that matters. Despite +16.2% revenue, gross profit rose only 8.8%, so gross margin compressed to 24.1%, and the company swung to a net and operating loss of -$5.90M from +$6.31M in FY2024 — a reversal of the FY2023–FY2024 profitable stretch. ROE is -4.5% and the accumulated deficit deepened 17.1% to -$40.3M. R&D up 25.8% and the doubling of capex to $3.87M signal investment, but the data doesn't isolate whether the margin collapse is integration/one-time cost or a structural pricing/mix problem — and the filing's emphasis on acquisition-driven Corporate G&A that is 'not directly allocable to the operating segments' is consistent with overhead outrunning gross profit.